ENTERED OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/020,436A

DATE: 05/16/2002
TIME: 17:02:30

Input Set : **A:\179-54.app**
Output Set: **N:\CRF3\05162002\J020436A.raw**

```
    3 <110> APPLICANT: CLARK, JONATHAN
    4        LAMONT, ALAN
    5        WILLIAMS, DAVID
    7 <120> TITLE OF INVENTION: A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES
    8        THAT COVALENTLY MODIFY SUBSTRATE MOLECULES
   10 <130> FILE REFERENCE: 179-54
   12 <140> CURRENT APPLICATION NUMBER: 10/020,436A
C--> 13 <141> CURRENT FILING DATE: 2002-05-16
   15 <150> PRIOR APPLICATION NUMBER: 09/530,431
   16 <151> PRIOR FILING DATE: 2000-07-26
   18 <150> PRIOR APPLICATION NUMBER: PCT/GB98/03259
   19 <151> PRIOR FILING DATE: 1998-10-30
   21 <150> PRIOR APPLICATION NUMBER: GB 9722818.3
   22 <151> PRIOR FILING DATE: 1997-10-30
   24 <160> NUMBER OF SEQ ID NOS: 19
   26 <170> SOFTWARE: PatentIn Ver. 2.1
   28 <210> SEQ ID NO: 1
   29 <211> LENGTH: 8
   30 <212> TYPE: PRT
   31 <213> ORGANISM: Artificial Sequence
   33 <220> FEATURE:
   34 <223> OTHER INFORMATION: Description of Artificial Sequence: Consensus
   35        peptide
W--> 37 <222> LOCATION:
   38 <223> OTHER INFORMATION: Biotin-epsilon-aminohexanoic acid is linked to the
   39        aspartic acid residue at position 1
   41 <220> FEATURE:
   42 <221> NAME/KEY: MOD_RES
W--> 43 <222> LOCATION: (8)
   44 <223> OTHER INFORMATION: Norleucine
W--> 46 <400> 1
W--> 47 Asp Glu Glu Asp Tyr Phe Glu Xaa
   48   1                   5
   51 <210> SEQ ID NO: 2
   52 <211> LENGTH: 36
   53 <212> TYPE: DNA
   54 <213> ORGANISM: Artificial Sequence
   56 <220> FEATURE:
   57 <223> OTHER INFORMATION: Description of Artificial Sequence: Primer
   59 <400> SEQUENCE: 2
   60 ccgggatccg ccatgcccat ggacacgagc gtgtat                        36
   63 <210> SEQ ID NO: 3
   64 <211> LENGTH: 57
```

RAW SEQUENCE LISTING   DATE: 05/16/2002
PATENT APPLICATION: US/10/020,436A   TIME: 17:02:30

Input Set : **A:\179-54.app**
Output Set: **N:\CRF3\05162002\J020436A.raw**

```
 65 <212> TYPE: DNA
 66 <213> ORGANISM: Artificial Sequence
 68 <220> FEATURE:
 69 <223> OTHER INFORMATION: Description of Artificial Sequence: Primer
 71 <400> SEQUENCE: 3
 72 gggggatcct cagtggtggt ggtggtggtg ggcacaggca gcctcagcct tctgtgt     57
 75 <210> SEQ ID NO: 4
 76 <211> LENGTH: 5
 77 <212> TYPE: PRT
 78 <213> ORGANISM: Artificial Sequence
 80 <220> FEATURE:
 81 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
 83 <400> SEQUENCE: 4
 84 Asp Glu Glu Asp Tyr
 85  1               5
 88 <210> SEQ ID NO: 5
 89 <211> LENGTH: 5
 90 <212> TYPE: PRT
 91 <213> ORGANISM: Artificial Sequence
 93 <220> FEATURE:
 94 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
 96 <400> SEQUENCE: 5
 97 Asp Glu Glu Tyr Phe
 98  1               5
101 <210> SEQ ID NO: 6
102 <211> LENGTH: 5
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
109 <400> SEQUENCE: 6
110 Asp Glu Tyr Glu Phe
111  1               5
114 <210> SEQ ID NO: 7
115 <211> LENGTH: 5
116 <212> TYPE: PRT
117 <213> ORGANISM: Artificial Sequence
119 <220> FEATURE:
120 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
122 <220> FEATURE:
123 <221> NAME/KEY: MOD_RES
124 <222> LOCATION: (5)
125 <223> OTHER INFORMATION: Norleucine
127 <400> SEQUENCE: 7
W-->  128 Asp Tyr Phe Glu Xaa
129  1               5
132 <210> SEQ ID NO: 8
133 <211> LENGTH: 5
134 <212> TYPE: PRT
```

RAW SEQUENCE LISTING   DATE: 05/16/2002
PATENT APPLICATION: US/10/020,436A   TIME: 17:02:30

        Input Set : A:\179-54.app
        Output Set: N:\CRF3\05162002\J020436A.raw

135 <213> ORGANISM: Artificial Sequence
137 <220> FEATURE:
138 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
140 <400> SEQUENCE: 8
141 Asp Glu Glu Asp Tyr
142   1   5
145 <210> SEQ ID NO: 9
146 <211> LENGTH: 5
147 <212> TYPE: PRT
148 <213> ORGANISM: Artificial Sequence
150 <220> FEATURE:
151 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
153 <400> SEQUENCE: 9
154 Asp Glu Glu Tyr Asp
155   1   5
158 <210> SEQ ID NO: 10
159 <211> LENGTH: 5
160 <212> TYPE: PRT
161 <213> ORGANISM: Artificial Sequence
163 <220> FEATURE:
164 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
166 <400> SEQUENCE: 10
167 Asp Glu Tyr Glu Asp
168   1   5
171 <210> SEQ ID NO: 11
172 <211> LENGTH: 5
173 <212> TYPE: PRT
174 <213> ORGANISM: Artificial Sequence
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
179 <400> SEQUENCE: 11
180 Asp Tyr Glu Glu Val
181   1   5
184 <210> SEQ ID NO: 12
185 <211> LENGTH: 5
186 <212> TYPE: PRT
187 <213> ORGANISM: Artificial Sequence
189 <220> FEATURE:
190 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
192 <220> FEATURE:
193 <221> NAME/KEY: MOD_RES
194 <222> LOCATION: (5)
195 <223> OTHER INFORMATION: Norleucine
197 <400> SEQUENCE: 12
W--> 198 Tyr Ser Ile Ile Xaa
199   1   5
202 <210> SEQ ID NO: 13
203 <211> LENGTH: 5
204 <212> TYPE: PRT

RAW SEQUENCE LISTING   DATE: 05/16/2002
PATENT APPLICATION: US/10/020,436A   TIME: 17:02:30

Input Set : A:\179-54.app
Output Set: N:\CRF3\05162002\J020436A.raw

```
205 <213> ORGANISM: Artificial Sequence
207 <220> FEATURE:
208 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
210 <400> SEQUENCE: 13
211 Asp Glu Glu Glu Tyr
212   1           5
215 <210> SEQ ID NO: 14
216 <211> LENGTH: 5
217 <212> TYPE: PRT
218 <213> ORGANISM: Artificial Sequence
220 <220> FEATURE:
221 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
223 <400> SEQUENCE: 14
224 Asp Glu Glu Tyr Phe
225   1           5
228 <210> SEQ ID NO: 15
229 <211> LENGTH: 5
230 <212> TYPE: PRT
231 <213> ORGANISM: Artificial Sequence
233 <220> FEATURE:
234 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
236 <400> SEQUENCE: 15
237 Asp Glu Tyr His Asn
238   1           5
241 <210> SEQ ID NO: 16
242 <211> LENGTH: 5
243 <212> TYPE: PRT
244 <213> ORGANISM: Artificial Sequence
246 <220> FEATURE:
247 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
249 <400> SEQUENCE: 16
250 Asp Tyr His Leu Phe
251   1           5
254 <210> SEQ ID NO: 17
255 <211> LENGTH: 5
256 <212> TYPE: PRT
257 <213> ORGANISM: Artificial Sequence
259 <220> FEATURE:
260 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
262 <400> SEQUENCE: 17
263 Tyr Pro Ile Glu Val
264   1           5
267 <210> SEQ ID NO: 18
268 <211> LENGTH: 5
269 <212> TYPE: PRT
270 <213> ORGANISM: Artificial Sequence
272 <220> FEATURE:
273 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
275 <400> SEQUENCE: 18
```

```
276 Ser Tyr Phe His Glu
277  1               5
280 <210> SEQ ID NO: 19
281 <211> LENGTH: 15
282 <212> TYPE: PRT
283 <213> ORGANISM: Artificial Sequence
285 <220> FEATURE:
286 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
287       peptide
289 <400> SEQUENCE: 19
290 Lys Lys Lys Lys Ala Asp Glu Glu Asp Tyr Phe Ile Pro Pro Ala
291  1               5                   10                  15
```

RAW SEQUENCE LISTING ERROR SUMMARY   DATE: 05/16/2002
PATENT APPLICATION: US/10/020,436A   TIME: 17:02:31

Input Set : **A:\179-54.app**
Output Set: **N:\CRF3\05162002\J020436A.raw**

<u>Please Note:</u>
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220>
to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 8
Seq#:7; Xaa Pos. 5
Seq#:12; Xaa Pos. 5

VERIFICATION SUMMARY
DATE: 05/16/2002
PATENT APPLICATION: **US/10/020,436A**
TIME: 17:02:31

Input Set : **A:\179-54.app**
Output Set: **N:\CRF3\05162002\J020436A.raw**

```
L:13  M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:37  M:281 W: Numeric Fields not Ordered, <222> Sort in ascending order!
L:46  M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1
L:47  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:128 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
L:198 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:0
```